Gemma Fisher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gemma Fisher has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Servais
University of Oxford
2 shared publications - Sithara Ramdas
Department of Paediatric Neurology John Radcliffe Hospital Oxford UK
2 shared publications - Theodora Markati
Institute of Developmental and Regenerative Medicine, Department of Paediatrics, University of Oxford, Oxford, OX3 7TY, UK
2 shared publications - Anna Sarkozy
The Dubowitz Neuromuscular Centre, University College London, and MRC Centre for Neuromuscular Diseases, Neurosciences Unit, Great Ormond Street Hospital, United Kingdom
1 shared publication - Heinz Jungbluth
Department of Paediatric Neurology, Neuromuscular Service, Evelina's Children Hospital, Guy's & St. Thomas' Hospital NHS Foundation Trust, London, United Kingdom
1 shared publication - Julien Ochala
Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
1 shared publication
Latest Publications
- Open Access
- 3 October 2022
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 26 (10) , 853-867
Early clinical and pre-clinical therapy development in Nemaline myopathy
: Nemaline myopathies (NM) represent a group of clinically and genetically heterogeneous congenital muscle disorders with the common denominator of nemaline rods on muscle biopsy. NEB and ACTA1 are...
- 3 October 2022
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 26 (10) , 853-867
Open AccessEarly clinical and pre-clinical therapy development in Nemaline myopathy
: Nemaline myopathies (NM) represent a group of clinically and genetically heterogeneous congenital muscle disorders with the common denominator of nemaline rods on muscle biopsy. NEB and ACTA1 are...
- Open Access
- 11 April 2022
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 31 (5) , 451-461
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)
Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease which is characterised by muscle atrophy and early death in most patients. Risdiplam is the third overall and first...
- 11 April 2022
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 31 (5) , 451-461
Open AccessRisdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)
Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease which is characterised by muscle atrophy and early death in most patients. Risdiplam is the third overall and first...